M. Rodriguez Garrote

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

IntroductionREG is a multi-kinase inhibitor that improves overall survival vs placebo in refractory mCRC. However, REG adverse tolerability profile often limits its use on normal clinica...

T. Cano ;

F. Loupakis ;

Josep Tabernero , MD, PhD;

M. Rodriguez Garrote ;

F. Herrero Rivera ;

R. Goldberg ;

J. Bennouna ;

Fortunato Ciardiello ;

A. Falcone ;

E. Aranda ;

G. Argiles ;

N. Mulet Margalef ;

M. Valladares-Ayerbes ;

J. Vieitez de Prado ;

C. Gravalos ;

P. Garcia Alfonso ;

C. Santos ;

M. Tobena ;

J. Sastre ;

M. Benavides ;

07/01/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

M. Rodriguez Garrote

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products